Journal of Veterinary Science

  • 제23권4호
  • /
  • Pages.61.1-61.10
  • /
  • 2022
  • /
  • 1229-845X(pISSN)
  • /
  • 1976-555X(eISSN)
대한수의학회 (The Korean Society of Veterinary Science)
권호 표지
DOI QR코드

DOI QR Code

Long-term treatment of allogeneic adipose-derived stem cells in a dog with rheumatoid arthritis

  • Seo, Min-Gyeong (Department of Veterinary Pathology, College of Veterinary Medicine, Gyeongsang National University) ;
  • Park, Seil (Cardiovascular Product Evaluation Center, College of Medicine, Yonsei University) ;
  • Han, Seonyoung (Department of Veterinary Pathology, College of Veterinary Medicine, Kyungpook National University) ;
  • Kim, Ah-Young (Department of Veterinary Pathology, College of Veterinary Medicine, Kyungpook National University) ;
  • Lee, Eun-Joo (Department of Veterinary Pathology, College of Veterinary Medicine, Kyungpook National University) ;
  • Jeong, Kyu-Shik (Department of Veterinary Pathology, College of Veterinary Medicine, Kyungpook National University) ;
  • Hong, Il-Hwa (Department of Veterinary Pathology, College of Veterinary Medicine, Gyeongsang National University)
  • 투고 : 2022.03.13
  • 심사 : 2022.06.17
  • 발행 : 2022.07.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Although there are growing demands for stem cell-based therapy for companion animals in various diseases, a few clinical trials have been reported. Moreover, most of them are the results from only one or a few times of stem cell injection. Objectives: The aim of this study is to describe a long-term treatment with allogeneic adipose-derived stem cells (ASCs) in a dog with rheumatoid arthritis (RA), which is a rare canine disease. Methods: The dog with RA received intravascular injection of allogeneic ASCs derived from two healthy donors once a month for 11 months. To assess therapeutic effects of ASCs, orthopedic examination and clinical evaluation was performed. Cytokines of tumor necrosis factor-α and interleukin-6 in the plasma were measured using ELISA analysis. Results: Despite this repeated and long-term administration of allogeneic ASCs, there were no side effects such as immunorejection responses or cell toxicity. The orthopedic examination score for the dog decreased after ASCs treatment, and the clinical condition of the dog and owner's satisfaction were very good Conclusions: Although ASCs has been suggested as one of the options for RA treatment because of its anti-inflammatory and immunosuppressive functions, it has never been used to treat RA in dogs. The present report describes a case of canine RA treated with allogeneic ASCs for long-term in which the dog showed clinical improvement without adverse effects.

키워드

과제정보

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (No. 2020R1A2C1102143).

참고문헌

  1. Craig LE, Dittmer KE, Thompson KG. Bones and joints. In: Maxie MG, editors. Jubb, Kennedy and Palmer's Pathology of Domestic Animals, Vol 1. 6th ed. Saint Louis: WB Saunders; 2016, 157-159.
  2. Stone M. Immune-mediated polyarthritis and other polyarthritides. In: Ettinger SJ, Feldman EC, editors. Textbook of Veterinary Internal Medicine: Diseases of the Dog and Cat, Vol 1. 8th ed. Saint Louis: WB Saunders; 2017, 2151-2160.
  3. Heuser W. Canine rheumatoid arthritis. Can Vet J. 1980;21(11):314-316
  4. Olson EJ, Carlson CS. Bones, joints, tendons, and ligaments. In: Zachary JF, editor. Pathologic Basis of Veterinary Disease. 6th ed. Saint Louis: Mosby; 2017, 1008.
  5. Wright HL, Moots RJ, Edwards SW. The multifactorial role of neutrophils in rheumatoid arthritis. Nat Rev Rheumatol. 2014;10(10):593-601. https://doi.org/10.1038/nrrheum.2014.80
  6. Brunner CJ. Automimmunity. In: Bonagura JD, editor. Kirk's Current Veterinary Therapy Small Animal Practice. 12th ed. Philadelphia: WB Saunders; 1995, 559-560.
  7. Lopez-Santalla M, Fernandez-Perez R, Garin MI. Mesenchymal stem/stromal cells for rheumatoid arthritis treatment: an update on clinical applications. Cells. 2020;9(8):1852. https://doi.org/10.3390/cells9081852
  8. Ruderman EM. Overview of safety of non-biologic and biologic DMARDs. Rheumatology (Oxford). 2012;51 Suppl 6:vi37-vi43.
  9. Dias IE, Pinto PO, Barros LC, Viegas CA, Dias IR, Carvalho PP. Mesenchymal stem cells therapy in companion animals: useful for immune-mediated diseases? BMC Vet Res. 2019;15(1):358. https://doi.org/10.1186/s12917-019-2087-2
  10. Ueyama H, Okano T, Orita K, Mamoto K, Ii M, Sobajima S, et al. Local transplantation of adiposederived stem cells has a significant therapeutic effect in a mouse model of rheumatoid arthritis. Sci Rep. 2020;10(1):3076. https://doi.org/10.1038/s41598-020-60041-2
  11. Gugjoo MB, Amarpal A, Sharma GT. Mesenchymal stem cell basic research and applications in dog medicine. J Cell Physiol. 2019;234(10):16779-16811. https://doi.org/10.1002/jcp.28348
  12. Black LL, Gaynor J, Gahring D, Adams C, Aron D, Harman S, et al. Effect of adipose-derived mesenchymal stem and regenerative cells on lameness in dogs with chronic osteoarthritis of the coxofemoral joints: a randomized, double-blinded, multicenter, controlled trial. Vet Ther. 2007;8(4):272-284.
  13. Gingerich DA, Strobel JD. Use of client-specific outcome measures to assess treatment effects in geriatric, arthritic dogs: controlled clinical evaluation of a nutraceutical. Vet Ther. 2003;4(1):56-66.
  14. Wasserman AM. Diagnosis and management of rheumatoid arthritis. Am Fam Physician. 2011;84(11):1245-1252.
  15. Johnson KC, Mackin A. Canine immune-mediated polyarthritis: part 2: diagnosis and treatment. J Am Anim Hosp Assoc. 2012;48(2):71-82. https://doi.org/10.5326/JAAHA-MS-5756
  16. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-2219. https://doi.org/10.1056/NEJMra1004965
  17. Ansboro S, Roelofs AJ, De Bari C. Mesenchymal stem cells for the management of rheumatoid arthritis: immune modulation, repair or both? Curr Opin Rheumatol. 2017;29(2):201-207. https://doi.org/10.1097/BOR.0000000000000370
  18. Karamini A, Bakopoulou A, Andreadis D, Gkiouras K, Kritis A. Therapeutic potential of mesenchymal stromal stem cells in rheumatoid arthritis: a systematic review of in vivo studies. Stem Cell Rev Rep. 2020;16(2):276-287. https://doi.org/10.1007/s12015-020-09954-z
  19. Hegemann N, Wondimu A, Kohn B, Brunnberg L, Schmidt MF. Cytokine profile in canine immunemediated polyarthritis and osteoarthritis. Vet Comp Orthop Traumatol. 2005;18(2):67-72. https://doi.org/10.1055/s-0038-1632931
  20. Kabat M, Bobkov I, Kumar S, Grumet M. Trends in mesenchymal stem cell clinical trials 2004-2018: is efficacy optimal in a narrow dose range? Stem Cells Transl Med. 2020;9(1):17-27. https://doi.org/10.1002/sctm.19-0202
  21. Kang MH, Park HM. Challenges of stem cell therapies in companion animal practice. J Vet Sci. 2020;21(3):e42. https://doi.org/10.4142/jvs.2020.21.e42
  22. Frese L, Dijkman PE, Hoerstrup SP. Adipose tissue-derived stem cells in regenerative medicine. Transfus Med Hemother. 2016;43(4):268-274. https://doi.org/10.1159/000448180
  23. Liang J, Li X, Zhang H, Wang D, Feng X, Wang H, et al. Allogeneic mesenchymal stem cells transplantation in patients with refractory RA. Clin Rheumatol. 2012;31(1):157-161. https://doi.org/10.1007/s10067-011-1816-0
  24. Alvaro-Gracia JM, Jover JA, Garcia-Vicuna R, Carreno L, Alonso A, Marsal S, et al. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial. Ann Rheum Dis. 2017;76(1):196-202. https://doi.org/10.1136/annrheumdis-2015-208918
  25. Wang L, Huang S, Li S, Li M, Shi J, Bai W, et al. Efficacy and safety of umbilical cord mesenchymal stem cell therapy for rheumatoid arthritis patients: a prospective phase I/II study. Drug Des Devel Ther. 2019;13:4331-4340. https://doi.org/10.2147/DDDT.S225613
  26. Chevrel G, Jenvrin C, McGregor B, Miossec P. Renal type AA amyloidosis associated with rheumatoid arthritis: a cohort study showing improved survival on treatment with pulse cyclophosphamide. Rheumatology (Oxford). 2001;40(7):821-825. https://doi.org/10.1093/rheumatology/40.7.821